Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Matloff

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Oncology|March 3, 2006
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort studySusan M Domchek, Tara M Friebel, Susan L Neuhausen, et al.
Cancer Research|July 22, 2010
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer riskElena Ratner, Lingeng Lu, Marta Boeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2005
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck, Tara Friebel, Theresa Wagner, et al.
Clinical Breast Cancer|February 14, 2008
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriersTara M Friebel, Susan M Domchek, Susan L Neuhausen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2008
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective studyNoah D Kauff, Susan M Domchek, Tara M Friebel, et al.
Breast Cancer Research and Treatment|February 25, 2010
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriersSusan M Domchek, Tara M Friebel, Judy E Garber, et al.
Breast Cancer Research and Treatment|October 15, 2014
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriersXinglei Chai, Tara M Friebel, Christian F Singer, et al.
JAMA|September 3, 2010
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek, Tara M Friebel, Christian F Singer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman, Wendy S Rubinstein, Sue Friedman, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Oncology|March 3, 2006
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort studySusan M Domchek, Tara M Friebel, Susan L Neuhausen, et al.
Cancer Research|July 22, 2010
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer riskElena Ratner, Lingeng Lu, Marta Boeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2005
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck, Tara Friebel, Theresa Wagner, et al.
Clinical Breast Cancer|February 14, 2008
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriersTara M Friebel, Susan M Domchek, Susan L Neuhausen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2008
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective studyNoah D Kauff, Susan M Domchek, Tara M Friebel, et al.
Breast Cancer Research and Treatment|February 25, 2010
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriersSusan M Domchek, Tara M Friebel, Judy E Garber, et al.
Breast Cancer Research and Treatment|October 15, 2014
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriersXinglei Chai, Tara M Friebel, Christian F Singer, et al.
JAMA|September 3, 2010
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek, Tara M Friebel, Christian F Singer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman, Wendy S Rubinstein, Sue Friedman, et al.
Pageof 2